NEWS
Promiliad Biopharma was awarded a Phase II STTR award
Promiliad Biopharma was awarded a Phase II STTR award Promiliad Biopharma was awarded a Phase II STTR award for $ 1,496,891 from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) to develop a new structural class of antibiotic. This two-year award, “Novel antibacterial agents derived from natural products” will help the company progress its triazolononactate antibiotic development program towards an IND application. The projects goals are to improve the potency and selectivity of our lead compound PBI-31-G-12 and to determine its mode of action. Compound PBI-31-G-12 is a completely novel structural type of antibiotic derived from our REBACS antibiotic generation programs.
Promiliad Biopharma was awarded a Phase II STTR award
Promiliad Biopharma was awarded a Phase II STTR award Promiliad Biopharma was awarded a Phase II STTR award for $ 1,496,891 from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) to develop a new structural class of antibiotic. This two-year award, “Novel antibacterial agents derived from natural products” will help the company progress its triazolononactate antibiotic development program towards an IND application. The projects goals are to improve the potency and selectivity of our lead compound PBI-31-G-12 and to determine its mode of action. Compound PBI-31-G-12 is a completely novel structural type of antibiotic derived from our REBACS antibiotic generation programs.